文献速递产科母胎医学

剖宫产后试产中缩宫素给药方案以最小化子宫破裂风险:一项系统综述与Meta分析

Oxytocin dosing during trial of labor after cesarean to minimize the risk of uterine rupture: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol MFM · 2025-11-13

该系统综述与Meta分析纳入21项观察性研究共51511例剖宫产后试产(TOLAC)患者,评估缩宫素使用及给药方案参数与子宫破裂(UR)风险的关联。结果显示缩宫素使用(任何使用、仅引产、仅加强宫缩)均与UR风险显著升高相关,剂量递增间隔<30分钟时UR风险一致升高,最大剂量≤20 mU/min和>20 mU/min均与风险增加相关且高剂量风险更大。作者建议采用较长递增间隔(≥30分钟)和限制最大剂量(≤20 mU/min)的方案,但需随机试验确认。

要点

  • TOLAC中缩宫素任何使用与UR风险升高相关(OR 1.94, 95%CI 1.36-2.77, P=.0003)。
  • 剂量递增间隔<30分钟时UR风险一致升高,较长间隔(≥30分钟)可能更安全。
  • 最大剂量≤20 mU/min和>20 mU/min均与UR风险增加相关,高剂量风险更大。

核心结论

  • TOLAC中缩宫素给药与子宫破裂风险增加相关,时机和累积暴露而非初始或增量剂量单独可能关键影响风险。
  • 采用较长递增间隔(≥30分钟)和限制最大剂量(≤20 mU/min)的方案可能提高TOLAC安全性。
  • 需要随机试验等可靠证据确认结果并确定TOLAC管理中最佳缩宫素方案。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase和Clinicaltrials.gov截至2024年9月21日。
  • 纳入评估缩宫素引产和/或加强宫缩与TOLAC中子宫破裂关联的随机和非随机研究,需报告至少一个缩宫素方案参数。
  • 共纳入21项观察性研究,51511例TOLAC患者。
  • 采用Mantel-Haenszel法随机效应模型合并OR及95%CI,按缩宫素暴露(任何使用、仅引产、仅加强)分三层分析。

主要发现

  • 任何使用缩宫素与UR风险显著升高相关(OR 1.94, 95%CI 1.36-2.77, P=.0003)。
  • 仅引产使用缩宫素与UR风险显著升高相关(OR 2.07, 95%CI 1.28-3.36, P=.003)。
  • 仅加强宫缩使用缩宫素与UR风险显著升高相关(OR 2.03, 95%CI 1.22-3.38, P=.007)。
  • 初始缩宫素剂量与UR风险无关系;增量≤2 mU/min仅在部分分析中显示显著关联,>2 mU/min亚组 consistently 检验效能不足。
  • 剂量递增间隔<30分钟时UR风险一致升高;最大剂量≤20 mU/min和>20 mU/min均与风险增加显著相关,高剂量风险更大。

关键数值与推荐

  • 缩宫素初始剂量亚组:≤2 vs >2 mU/min。
  • 缩宫素增量亚组:≤2 vs >2 mU/min。
  • 剂量递增间隔亚组:<30 vs ≥30分钟。
  • 最大剂量亚组:≤20 vs >20 mU/min。

临床怎么用

  • 作者建议采用较长剂量递增间隔(≥30分钟)和限制最大剂量(≤20 mU/min)的方案可能提高TOLAC安全性。
  • 作者认为需要随机试验确认结果并确定TOLAC管理中最佳缩宫素方案。

局限性

  • >2 mU/min增量亚组 consistently 检验效能不足。
  • 需要随机试验等可靠证据确认结果并确定最佳缩宫素方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Oxytocin remains the mainstay for induction and for the management of labor arrest during trial of labor after cesarean (TOLAC). Therefore, the clinical question should be not whether to use oxytocin, but how to optimize its administration. This meta-analysis aimed to assess which oxytocin protocol, in terms of initial dose, amount of increase, timing to next increase, and maximum dose, may minimize the risk of uterine rupture (UR) during TOLAC. DATA SOURCES: PubMed, Embase and Clinicaltrials.gov were searched up to September 21, 2024. STUDY ELIGIBILITY CRITERIA: Randomized and nonrandomized studies evaluating the association between induction and/or augmentation with oxytocin and UR during TOLAC versus spontaneous TOLAC were eligible. To be included, studies had to report at least one parameter of the oxytocin protocol used (ie, initial dose, amount of increase, timing to next increase, or maximum dose). The primary outcome was UR. METHODS: Effect measures were expressed as odds ratios (ORs) with 95% confidence intervals (CIs) and pooled using the Mantel-Haenszel method under a random-effects model. Oxytocin exposure was categorized to perform three separate meta-analyses, ie, any use (for induction and/or augmentation), for induction only, and for augmentation only. In all three comparisons, subgroup analyses assessed differences based on oxytocin initial dose (≤2 vs >2 mU/min), amount of increase (≤2 vs >2 mU/min), timing to next increase (<30 vs ≥ 30 minutes), and maximum dose (≤20 vs >20 mU/min). RESULTS: Twenty-one observational studies with 51,511 patients undergoing TOLAC were included. Oxytocin use during TOLAC was consistently associated with a significantly higher risk of UR across all analyses (any use: OR 1.94, 95% CI 1.36-2.77, P=.0003; induction only: OR 2.07, 95% CI, 1.28-3.36, P=.003; augmentation only: OR 2.03, 95% CI 1.22-3.38; P=.007). Among oxytocin protocol parameters, the initial oxytocin dose showed no relationship with UR risk. A significant association was found in some analyses only for increments ≤2 mU/min, though the >2 mU/min subgroup was consistently underpowered. A higher risk of UR was uniformly observed when dose escalations were performed at intervals <30 minutes. Both moderate (≤20 mU/min) and high (>20 mU/min) maximum doses were significantly associated with increased odds, with a greater risk at higher doses. CONCLUSIONS: These findings showed an association between oxytocin dosing during TOLAC and an increased risk of UR. Specifically, they suggest that both the timing and cumulative exposure of oxytocin, rather than the initial or incremental dose alone, may critically influence UR risk during TOLAC. Protocols adopting longer escalation intervals (≥30 minutes) and limiting maximum doses (≤20 mU/min) may enhance safety during TOLAC. Reliable evidence, such as that from randomized trials, is required to confirm these results and define the optimal oxytocin regimen in TOLAC management. El resumen está disponible en Español al final del artículo.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Nicolì P, Gulersen M, Beacham J, et al. Oxytocin dosing during trial of labor after cesarean to minimize the risk of uterine rupture: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2025. PMID: 41241095. doi:10.1016/j.ajogmf.2025.101846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。